26 August 2016 - - US-based immuno-oncology company TapImmune Inc. (OTC: TPIV) has appointed Michael J. Loiacono as its chief financial officer and chief accounting officer, the company said.

Loiacono will also act as corporate secretary. Michael has served an advisory role to the company as finance consultant to TapImmune since March 2016.

He served as CFO of Global Axcess Corp., a publicly-traded company, from 2006-2013 where he was responsible for the overall strategy of the company including capital raises, mergers and acquisitions, corporate finance, treasury, accounting and investor relations.

Upon the acquisition of Global Axcess by FCTI, Inc., he was responsible for the company's strategic development including new products and services, entrance into new markets and maximizing gross and net revenues.

In 2009, he was named the "Jacksonville Florida Ultimate CFO of the year" by the Jacksonville Business Journal.

Prior to Global Axcess/FCTI Michael held various positions of increasing responsibility in finance management through several private and publicly-traded organizations.

TapImmune is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease.

The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems.

TapImmune's technologies may be used as stand-alone medications or in combination with current treatment modalities.